Tattoo Pharma OÜ

16127240

Company info

Tattoo Pharma OÜ

16127240

Tattoo Pharma. Professional care for your tattoo at any step of its existencehttps://tattoo-pharma.comTattoo Pharma. Professional care for your tattoo at any step of its existence

Tattoo Pharma is the first company in Russia developed healing and aftercare products for tattoed skin. Since 2014 we have been producing certified products for effective work and professional tattoo care.

General info

Name

Tattoo Pharma OÜ

Registry code

16127240

VAT number

EE102348288

Type

OÜ - Limited Liability Company

Status

Registered

Foundation date

27.12.2020 (3)

Financial year

01.01-31.12

Capital

2 500.00 €

Activity

46451 - Wholesale of perfume and cosmetics

Revenue

23 686 €

Profit

8 860 €

Profit margin

37%

Gross salary

-

Equity

26 173 €

Employees

0

Annual report

Submitted

Tax arrears

No tax arrears

Return on equity

34%

Return on assets

29%

Related parties

Owner Representative Beneficial owner Roles

Alexey Tupolev

29.10.1980 (43)

100% - 2 500.00 EUR Board member - Founder

PRIVATE FINANCIAL SERVICES OÜ

12461485

- Contact person -

Financial info

2021
16.06.2022
2022
27.06.2023
2023
29.05.2024
Total Revenue 15 380 € 55 337 € 23 686 €
Net profit (loss) for the period 3 248 € 11 566 € 8 860 €
Profit Margin 21% 21% 37%
Current Assets 15 015 € 20 702 € 31 043 €
Fixed Assets - - -
Total Assets 15 015 € 20 702 € 31 043 €
Current Liabilities 9 267 € 3 388 € 4 870 €
Non Current Liabilities - - -
Total Liabilities - - -
Share Capital - - -
Equity 5 748 € 17 314 € 26 173 €
Employees 0 0 0

Paid taxes, taxable turnover and number of employees

Turnover
State taxes
Labor taxes and payments
Employees
2024 Q1 799.5 € - - -
2023 Q4 784 € 104.78 € - -
2023 Q3 2 922.4 € - - -
2023 Q2 9 210.19 € - - -
2023 Q1 13 902.9 € - - -
2022 Q4 32 129.76 € 2 410.34 € - -
2022 Q3 19 053.58 € 167 € - -
2022 Q2 12 202.62 € - - -
2022 Q1 20 941.71 € 138.46 € - -
2021 Q4 2 749.2 € 67.53 € - -
2021 Q3 2 802.5 € 226.97 € - -
2021 Q2 - - - -
2021 Q1 - - - -